Loading…

Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2023-06, Vol.41 (S2), p.484-486
Main Authors:	Wallace, D. S., Rowland, C., Hill, B. T., Baran, A. M., Casulo, C., Reagan, P. M., Winter, A., Karmali, R., Winter, J. N., Gordon, L. I., Bui, A., Sportelli, P., Weiss, M. S., Miskin, H. P., Friedberg, J. W., Ma, S., Barr, P. M.
Format:	Article
Language:	English
Subjects:	Lymphoma Mantle cell lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!